3-甲基-1,2-二氢异喹啉 | 59816-89-6

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 3-甲基-1,2-二氢异喹啉
• 英文名称: 3-methyl-1,2-dihydro-isoquinoline
• 英文别名: 3-Methyl-1,2-dihydro-isochinolin；3-Methyl-1,2-dihydroisoquinoline
• CAS: 59816-89-6
• 化学式: C₁₀H₁₁N
• mdl: MFCD19219028
• 分子量: 145.204
• InChiKey: WPUGJRMMUDEGMK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  2-氨基甲基苯乙酸 在 soda lime 、 alkaline solution 作用下， 生成 3-甲基-1,2-二氢异喹啉
  参考文献：
  名称：

  Haginiwa et al., Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1959, vol. 79, p. 1578,1581

  摘要：

  DOI：

文献信息

• Novel and Facile Reduction of Heterocyclic Compounds with Lanthanoid Metal-Hydrochloric Acid System.
  作者：Yasuko KAMOCHI、Tadahiro KUDO

  DOI：10.1248/cpb.43.1422

  日期：——

  Pyridines were rapidly reduced to piperidines with Sm or Yb-HCl system at room temperature in quantitative yields. Quinolines and isoquinolines were similarly reduced to the corresponding 1, 2, 3, 4-tetrahydro-derivatives with Sm-HCl system in good yields.

  吡啶类化合物在室温下通过Sm或Yb-HCl体系迅速还原为哌啶类化合物，产率定量。喹啉和异喹啉同样通过Sm-HCl体系被还原为对应的1,2,3,4-四氢衍生物，产率良好。
• New utilities of amide compounds
  申请人：Yamamori Teruo

  公开号：US20080221112A1

  公开（公告）日：2008-09-11

  Compounds having an activity to enhance the expression of apoAI are provided, which are used as medicaments. Compounds of formula (I): in which ring A and Ar 1 are independently a monocyclic or bicyclic aromatic carbocyclic group or aromatic heterocyclic group, each of which may be optionally substituted, or the like; R is a hydrogen or the like; Z is oxygen or the like; Y 1 and Y 2 are a hydrogen, a lower alkyl, or the like; n is an integer of 0 to 2; the broken line is the presence or absence of a bond; and the wavy line represents a cis- or trans-geometrical isomerism with respect to the double bond; are disclosed.
• US7429593B2
  申请人：——

  公开号：US7429593B2

  公开（公告）日：2008-09-30
• US8106051B2
  申请人：——

  公开号：US8106051B2

  公开（公告）日：2012-01-31
• [EN] CDK9 INHIBITORS IN THE TREATMENT OF MIDLINE CARCINOMA<br/>[FR] INHIBITEURS DE CDK9 POUR TRAITER LE CARCINOME DE LA LIGNE MÉDIANE
  申请人：LEAD DISCOVERY CENTER GMBH

  公开号：WO2013026874A1

  公开（公告）日：2013-02-28

  The present invention relates to a CDK9 inhibitor, especially a selective CDK9 inhibitor, for use in treating, ameliorating and/or preventing midline carcinoma. Also corresponding methods for treating, preventing or ameliorating midline carcinoma are subject of the present invention. Preferably, NUT midline carcinoma is treated with the CDK9 inhibitors in accordance with the present invention.